phosphocholine (DOPC), and cholesterol were purchased from Avanti Polar Lipids Inc.
(USA). BCA protein assay kit was obtained from Beyotime (Shanghai, China). All other organic reagents were purchased from Sinopharm Chemical Reagent Co., Ltd.
(China). All solutions were prepared using ultrapure water (18.2 MΩ resistivity) as the solvent.
Cell culture and animals. Human breast carcinoma MCF-7 cells, Human epithelial carcinoma HeLa cells and mouse macrophage RAW264.7 cells were purchased from ATCC (American Type Culture Collection). MCF-7 cells were cultured in RPMI-1640 medium (Gibco) with 10% FBS (Gibco) at 37 °C in a humidified atmosphere with 5% CO 2 . HeLa cells and RAW264.7 cells were grown in DMEM containing 10% FBS, 100 U/mL penicillin G sodium, and 100 g/mL streptomycin sulfate at 37 °C in a humidified incubator with 5% CO 2 . Animals received care in accordance with the guidelines approved by the Institutional Animal Care and Use Committee (IACUC) of the Shanghai Institute of Materia Medica, CAS. Female BALB/c nude mice and female ICR mice were purchased from Shanghai Experimental Animal Center (Shanghai).
Extraction of membrane proteins from MCF-7 cancer cells and red blood cells.
MCF-7 cancer cell membranes and red blood cell membranes were achieved by hypotonic lysis, mechanical membrane disruption and then differential centrifugation,
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according to a previously reported extrusion approach. To obtain membrane proteins, the membrane material was added to membrane protein extraction reagents and incubated at 4 °C for 1 h. The hybrid membrane proteins contain MCF-7 cancer cell membrane proteins and red blood cell membrane proteins at 1:1 mass ratio.
Preparation of biomimetic artificial chimeric exosomes (ACEs). ACEs were prepared by the thin layer evaporation (TLE) method and extrusion process. Briefly, 10.8 mg DPPC, 2.4 mg DSPC, 7.2 mg DOPC, 1.2 mg cholesterol (Avanti Polar Lipids) and 0.25 mg ICG were dissolved in 2 mL organic mixture containing 1.5 mL chloroform and 0.5 mL methanol. Then the solvent was evaporated through an IKA Rotary Evaporator RV10 (IKA, Germany) to form a thin film. Films were hydrated with 70 g of hybrid membrane proteins, MCF-7 cancer cell membrane proteins, or red blood cell membrane proteins dispersed in PBS to assemble ACEs, AMEs or AREs, respectively, by heating and vortexing at 45 °C for 20 min. Conventional liposomes were prepared as described above with PBS alone. Lipid suspension was then extruded 20 times through cellulose acetate membranes (100 nm pore-size) at 45 °C, using a mini-extruder (Avanti Polar Lipids Co. Ltd., USA). The encapsulation of DOX was achieved by the (NH 4 ) 2 SO 4 gradient method. The obtained vesicles were then dialyzed overnight through a 1000 kDa dialysis bag to eliminate raw material and unincorporated proteins.
Characterization of biomimetic artificial chimeric exosomes (ACEs). Vesicle size and zeta potential of liposomes, AREs, AMEs and ACEs were measured using a Zetasizer Nano ZS instrument (Malvern, England). The morphology of liposomes,
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AREs, AMEs and ACEs was determined using an FEI Tecnai G20 microscope (FEI NanoPorts, USA) after staining with 3% (w/v) phosphotungstic acid. Encapsulation efficiency was determined using a Shimadzu LC-20AT HPLC system (Japan) with a reverse phase C-18 Ultra sphere ODS column (250 × 4.6 mm, 5 mm, Beckman, USA). 
Atomic

Stability test of ACEs in PBS and FBS. Liposomes, AREs, AMEs and ACEs solution
(10 mg/mL) was respectively prepared and mixed with PBS and 20% FBS. The mixture was incubated at 37 °C, and vesicle size was determined at intervals using DLS.
In vitro drug release. Liposomes, AREs, AMEs and ACEs fabricated as described above were dissolved in PBS, sealed in dialysis tubes (MWCO = 3.5 kDa), and then dialyzed in 57 mL of PBS with 2% Tween 80. At predetermined time points, a 100 L aliquot of the solution outside the dialysis tube was withdrawn, and DOX concentration was determined using HPLC analysis. In vitro cellular uptake of macrophage RAW264.7 cells. To evaluate the cellular uptake of mouse macrophage RAW264.7 cells, the cells were incubated with liposomes, AREs, AMEs and ACEs at a DOX dose of 10 M for 2 h. Subsequently, the cells were washed with PBS and fixed with 4% paraformaldehyde for 30 min before imaging using a CLSM microscope (Nikon A1, Japan).
In vitro cytotoxicity assay. In a typical experiment, MCF-7 cells were seeded in 96-well plates and then incubated with 100 L of varying concentrations of liposome, AREs, AMEs and ACEs without DOX for 24 h at 37 o C in a humidified 5% CO 2 atmosphere. Cell viability was determined by the CCK-8 method according to the manufacturer's protocol. The in vitro cytotoxicity assay was performed using a similar procedure, except that MCF-7 cells were incubated with liposomes, AREs, AMEs and ACEs, and the final concentration of DOX in all formulations was in the range of 10 to 1 × 10 -4 g/mL. In vivo biodistribution. In the drug biodistribution experiments, female BALB/c nude mice were subcutaneously injected with 1 × 10 7 MCF-7 cells on the back of the hind leg. When the tumor volume reached 200 mm 3 , the mice were randomly divided into four groups (n = 3) and intravenously injected with liposomes, AREs, AMEs and ACEs at a DOX dose of 6 mg/kg. Twenty-four h after treatment, the mice were sacrificed, and the major organs, including heart, liver, spleen, lung, kidneys, and tumor, were collected for DOX analyses. The organs or tissues were washed with 0.9% saline before being weighed and then cut into small pieces and homogenized. Two hundred μL of ice-cold acetonitrile containing 0.5% acetic acid were used to extract DOX, and then the mixture was centrifuged at 13,000 rpm for 10 min. Finally, the supernatant was concentrated and subjected to HPLC to determine DOX levels, and the corresponding DOX tissue concentrations were calculated accordingly.
In vivo pharmacokinetics. In the plasma pharmacokinetic study, female ICR mice were randomly assigned to 4 groups (n = 3) and intravenously injected with liposomes, AREs, AMEs and ACEs, respectively, at a DOX dose of 6 mg/kg. Blood samples were collected into heparinized tubes at 15 and 30 min and 1, 2, 4, 8, 12 and 24 h after administration and centrifuged at 5,000 rpm and 4 °C for 10 min to harvest plasma samples. Acetonitrile was added to the samples to precipitate all proteins and extract S8 the content of the drug. After centrifugation, the organic layer was collected and concentrated, followed by examination of the DOX concentration using HPLC analysis. Tumor growth curves were plotted using the average tumor volume versus days after the first treatment. All mice were sacrificed at the end of the experiment, and their tumors were resected and imaged. H&E Histology. At the end of the experiment, tumor-bearing mice were sacrificed, and the tumor, heart, liver, spleen, lung, and kidney were collected for H&E assays to evaluate the histopathologic toxicity of the tissues.
In vivo
Statistical Analyses. Data were presented as mean ± standard deviation (SD).
Statistical comparisons were performed using unpaired Student's t test for two group comparisons. Differences were considered statistically significant when p < 0.05.
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Supporting Tables: Table S1 . DOX and ICG encapsulation efficiency (EE) Table S2 . Pharmacokinetic parameters of DOX following intravenous administration of liposomes, AREs, AMEs and ACEs at the dose of 6 mg/kg (n =3 for each administration). 
